Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation

@article{Rapaport2006EffectsOR,
  title={Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation},
  author={Mark Hyman Rapaport and Georges M Gharabawi and Carla M Canuso and Ramy Mahmoud and Martin B. Keller and Cynthia A. Bossie and Ibrahim Turkoz and Robert A. Lasser and Amy Loescher and Philippe Bouhours and Fiona Dunbar and Charles B. Nemeroff},
  journal={Neuropsychopharmacology},
  year={2006},
  volume={32},
  pages={1208-1208}
}
Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label… CONTINUE READING
51 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

Similar Papers

Loading similar papers…